Clinical trials
Opioid Use Disorder, Moderate clinical trials
Below are recruiting opioid use disorder, moderate clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07684976Recruiting
Safety of a helmet device using ultrasound for substance use disorder
This study tests a special helmet that uses focused ultrasound to stimulate parts of the brain involved in addiction. It aims to see if the treatment is safe and works for people with moderate to severe substance use disorder who have not gotten enough help from standard medication treatments.
Toronto, OntarioAges 18–70 - NCT07559500RecruitingPhase 1
Study of tirzepatide for alcohol use disorder
This trial tests if tirzepatide, a diabetes drug, affects brain chemistry linked to alcohol use. Researchers want to see if it can help people with mild-to-moderate alcohol use disorder who also have tried stimulants.
Bethesda, MarylandAges 21–65 - NCT06479681Recruiting
Coaching help for alcohol use recovery in hospital
This trial tests if a peer recovery coach can help people with alcohol use disorder stay sober after being hospitalized. You'll get support from someone who has been through recovery themselves.
Greenville, South CarolinaAges 18–75 - NCT05042102RecruitingPhase 2
Donepezil plus brain training for alcohol use disorder
This Phase 2 study tests whether donepezil, along with structured cognitive (brain) training, can improve outcomes for people with alcohol use disorder. It will measure whether this combination helps after recent heavy drinking, while tracking safety over about 13 weeks.
West Haven, ConnecticutAges 18–80 - NCT05613608RecruitingPhase 2/Phase 3
Cannabidiol (CBD) study for alcohol use disorder
This trial tests whether cannabidiol (CBD) can help people cut down or quit drinking alcohol. It enrolls adults diagnosed with alcohol use disorder and wanting to reduce drinking, while checking for safety and other mental health or drug use factors.
Aurora, ColoradoAges 21 years+ - NCT07262190Recruiting
NavSTAR program for opioid use disorder
This trial tests a program to help people with opioid use disorder start or continue treatment while in the hospital. It aims to connect patients to care after they leave.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07176351RecruitingPhase 4
Monthly buprenorphine injections from a mobile clinic
This study tests a new way to receive buprenorphine—a once-a-month injection—from a mobile clinic that comes to you. It aims to make treatment more convenient and acceptable for people with opioid use disorder.
New Haven, ConnecticutAges 18 years+ - NCT06877858RecruitingPhase 1
MethaLoad dose-finding study for opioid use disorder
This study tests a new way to start methadone treatment (called 'MethaLoad') for people with opioid use disorder who have used fentanyl. If you qualify, you will receive methadone to help manage withdrawal and reduce cravings, and the doctors will closely monitor your safety and response.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06810310RecruitingPhase 2
Psilocybin for motivation in opioid use disorder
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
Philadelphia, PennsylvaniaAges 18–60 - NCT06799117Recruiting
Decision Support for Opioid Addiction Treatment
This study tests a new way to help people in the emergency department who have moderate to severe opioid use disorder. It looks at using a decision-support tool to guide treatment choices.
Guilford, ConnecticutAges 18 years+ - NCT06786325RecruitingPhase 2
Psilocybin treatment study for opioid use disorder
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Philadelphia, PennsylvaniaAges 18–60 - NCT06494904RecruitingPhase 3
Standard vs. High Dose Buprenorphine in the ER
This study compares a higher dose of buprenorphine (a medicine that helps stop opioid cravings and withdrawal) to the usual dose, given in the emergency department. It aims to see if the higher dose works better to start treatment for opioid use disorder.
Oakland, CaliforniaAges 18–65 - NCT06306443RecruitingPhase 3
Buprenorphine treatment for people leaving jail
This trial offers buprenorphine (a medication for opioid use disorder) to people in jail who are soon to be released. It helps you start treatment while incarcerated and continue it after you return to the community, aiming to reduce overdose and improve recovery.
Baltimore, MarylandAges 18 years+ - NCT06136247Recruiting
Brain & thinking tests in opioid use disorder
This study tests whether brain scans and thinking tests can help understand opioid use disorder. It is for people on stable buprenorphine or methadone treatment.
Philadelphia, PennsylvaniaAges 18–60 - NCT05589181RecruitingPhase 3
High-dose buprenorphine start in the emergency department for fentanyl use
This Phase 3 study tests whether starting a high dose of buprenorphine in the emergency department helps people with opioid use disorder come through withdrawal more safely and effectively. It focuses on people whose urine test shows fentanyl and who are already in withdrawal when they arrive.
Newark, New JerseyAges 18 years+ - NCT04379115Recruiting
Brain stimulation study for people with opioid addiction
This study tests a non-invasive brain stimulation approach to reduce opioid cravings in people who are actively using non-prescribed opioids while on stable methadone. It may help people feel less craving and improve recovery support.
Hinsdale, IllinoisAges 18–85 - NCT04161066RecruitingPhase 1
Psilocybin plus buprenorphine to help opioid use disorder symptoms
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Madison, WisconsinAges 21–65 - NCT06405607RecruitingPhase 2
Psilocybin vs Ketamine for Alcohol Use Disorder Trial
This trial tests two psychedelic-assisted therapies, psilocybin and ketamine, to see which works better for reducing heavy drinking in people with alcohol use disorder (AUD). You'll receive either drug along with counseling, and the study monitors safety closely.
Iowa City, IowaAges 21–65 - NCT06484075RecruitingPhase 1/Phase 2
Sleep medication for alcohol use disorder
This study tests whether suvorexant, a sleep aid, can help people with alcohol use disorder by looking at brain changes. It may improve sleep and reduce drinking.
Bethesda, MarylandAges 18–75 - NCT05538910Recruiting
Brain imaging study on substance use and depression
This study uses brain scans to understand how substance use and mental illness, like depression, are linked. It may help develop better treatments by looking at brain activity in people with and without depression.
Baltimore, MarylandAges 18–60 - NCT05525598Recruiting
Online therapy for severe body–mind symptom disorders
This trial tests an internet-based treatment program for people with moderate-to-severe functional somatic disorders (long-lasting physical symptoms linked to how the body and brain interact). It may help reduce symptoms and improve day-to-day functioning by offering structured support online.
Aarhus C, DenmarkAges 18–60 - NCT07773649RecruitingEarly Phase 1
PET scan to study energy use in brain of people with cocaine use disorder
This study uses a special PET scan to look at how brain cells make energy, which may be changed by cocaine. It might help researchers find better ways to treat cocaine use disorder.
Pittsburgh, PennsylvaniaAges 18–45 - NCT07040592RecruitingPhase 2
Semaglutide for HIV and alcohol use
This study is testing whether semaglutide, a medication already used for diabetes and weight loss, can help people with HIV who also have an alcohol use disorder cut back on drinking. It is for patients treated at the Atlanta VA Healthcare System.
Decatur, GeorgiaAges 18–99 - NCT06788587RecruitingPhase 2
Long-term stimulant for methamphetamine recovery
This study tests whether a high dose of a stimulant medication (lisdexamfetamine, an ADHD medicine) taken over many weeks can help people who have already completed a methamphetamine treatment program to stay off meth, reduce use, or avoid relapse.
Montreal, QuebecAges 18–55
Hear when a new Opioid Use Disorder, Moderate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for opioid use disorder, moderate?
- Yes. Clin2 currently lists 87 recruiting opioid use disorder, moderate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a opioid use disorder, moderate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a opioid use disorder, moderate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.